E-therapeutics Plc
ETXPF · OTC
7/31/2024 | 1/31/2024 | 7/31/2023 | 1/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.15 | 18.74 | -0.31 | -0.71 |
| FCF Yield | -11.40% | -4.20% | -5.05% | -2.70% |
| EV / EBITDA | -4.22 | -12.26 | -16.83 | -12.73 |
| Quality | ||||
| ROIC | -19.92% | -25.99% | -16.64% | -11.89% |
| Gross Margin | 0.00% | -67.09% | -69.37% | 100.00% |
| Cash Conversion Ratio | 1.00 | 1.23 | 0.65 | 1.17 |
| Growth | ||||
| Revenue 3-Year CAGR | -25.78% | -1.70% | 15.37% | 37.04% |
| Free Cash Flow Growth | -102.18% | 39.63% | -126.22% | 39.40% |
| Safety | ||||
| Net Debt / EBITDA | 5.59 | 3.23 | 3.90 | 7.02 |
| Interest Coverage | 179.51 | -296.70 | -1,742.50 | -516.73 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.03 | 0.00 |
| Cash Conversion Cycle | -503.90 | -370.90 | 2,448.52 | 0.00 |